Busulfan, etoposide, cytarabine, and melphalan (BuEAM) as a conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma (NHL)

被引:0
作者
Jae-Cheol Jo
Jin Seok Kim
Je-Hwan Lee
Jung-Hee Lee
Sung-Nam Lim
Sang Min Lee
Sung-Soo Yoon
In-Ho Kim
Sung Hwa Bae
Yoo Jin Lee
Yunsuk Choi
Won-Sik Lee
机构
[1] University of Ulsan College of Medicine,Department of Hematology and Oncology, Ulsan University Hospital
[2] Yeonsei University College of Medicine,Department of Internal Medicine, Severance Hospital
[3] University of Ulsan College of Medicine,Department of Hematology, Asan Medical Center
[4] College of Medicine Inje University,Department of Internal Medicine, Haeundae Paik Hospital
[5] Inje University College of Medicine,Department of Hematology and Oncology, Busan Paik Hospital
[6] Seoul National University College of Medicine,Department of Hematology and Oncology, Seoul National University Hospital
[7] Catholic University of Daegu School of Medicine,Department of Hematology and Oncology, Daegu Catholic University Hospital
来源
Bone Marrow Transplantation | 2020年 / 55卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:1466 / 1468
页数:2
相关论文
共 63 条
[1]  
Jo JC(2008)BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin’s lymphoma patients: comparative analysis of efficacy and toxicity Ann Hematol 87 43-8
[2]  
Kang BW(2011)BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin’s lymphoma patients: a single center comparative analysis of efficacy and toxicity Leuk Res 35 183-7
[3]  
Jang G(2012)Yttrium-90 ibritumomab tiuxetan plus busulfan, cyclophosphamide, and etoposide (BuCyE) versus BuCyE alone as a conditioning regimen for non-Hodgkin lymphoma Korean J Hematol 47 119-25
[4]  
Sym SJ(2014)Busulfan-containing conditioning regimens are optimal preparative regimens for autologous stem cell transplant in patients with diffuse large B-cell lymphoma Leuk Lymphoma 55 2490-6
[5]  
Lee SS(1995)BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin’s lymphoma J Clin Oncol 13 588-95
[6]  
Koo JE(2012)Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma J Clin Oncol 30 4462-9
[7]  
Kim JE(2004)Autologous stem-cell transplantation in diffuse large B-cell non-Hodgkin’s lymphoma not achieving complete response after induction chemotherapy: the GEL/TAMO experience Ann Oncol 15 1504-9
[8]  
Lee DH(2016)Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning Leuk Lymphoma 57 2499-509
[9]  
Yoo C(2012)Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01 J Clin Oncol 30 3093-9
[10]  
Kim S(2012)Mitoxantrone, etoposide, cytarabine, and melphalan (NEAM) followed by autologous stem cell transplantation for patients with chemosensitive aggressive non-Hodgkin lymphoma Am J Hematol 87 479-83